Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 227Myeloid 98Lymphoid 44Gastrointestinal 10Dermatologic 9Classical hematology 9Thoracic 7Gynecologic 7Other solid neoplasm 6Head & Neck 6Genitourinary 6Other neoplasm 5Breast 5Sarcoma 4Tumor-Agnostic 3CNS 3Plasma cell 1Endocrine 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Decitabine × Tumor-Agnostic × Clear all
NCT04292769 2020-03-03

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

Chinese PLA General Hospital

Phase 3 Unknown
200 enrolled
Tumor-Agnostic

Neoplasms

NCT02499861 2017-11-17

Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies

St. Justine's Hospital

Phase 1/2 Completed
6 enrolled
Tumor-Agnostic

Neoplasms

NCT00886457 2011-07-20

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

Nevada Cancer Institute

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡